Monopar Therapeutics price target raised to $22 from $6 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Monopar Therapeutics (MNPR) to $22 from $6 and keeps a Buy rating on the shares. The ...
IonQ: Quantum Networking Milestones Spark A Bull Run
IonQ aims to lead the quantum networking market with two key milestones achieved this year. Read more about IONQ stock here.
Transformative Licensing Acquisition Drives Buy Rating for Monopar Therapeutics
Analyst Sean Lee CFA of H.C. Wainwright maintained a Buy rating on Monopar Therapeutics Inc (MNPR – Research Report), boosting the price ...
Alteogen Enters Into An Exclusive License Agreement To Develop And Commercialize Subcutaneous ENHERTU® Enabled By Alteogen's Hybrozymetm Technology
ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...
pharmaphorum20h
Pfizer makes 'final' £69 billion bid for AstraZeneca
Pfizer has made a new and improved bid to acquire AstraZeneca with an offer worth £69.3 billion pounds ($116.6 billion) or £55 a share – and says this is its best and final offer for the firm.
Angle PLC Announces Parsortix enriched CTC & ctDNA in NSCLC patients
ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIB The addition of CTC-DNA analysis to clinical trials could identify patients ...
pharmaphorum7h
The evolving role of AI in drug submission and approval: An expert perspective
The integration of AI into drug submission and approval processes signifies a shift towards more efficient pharmaceutical ...
Government cuts NatWest stake to 11.4% with £1bn share sale
The Government has agreed the £1billion sale of a proportion of the taxpayer's stake in NatWest, as the lender resumes its ...